Immunomodulation through anti-inflammatory signaling pathways

"Immunomodulation through anti-inflammatory signaling pathways" refers to the therapeutic manipulation of intracellular communication systems that regulate inflammation and immune responses. These pathways, including but not limited to the nuclear factor kappa-B (NF-κB), mitogen-activated protein kinase (MAPK), Janus kinase-signal transducer and activator of transcription (JAK-STAT), AMP-activated protein kinase (AMPK), and NLRP3 inflammasome pathways, are crucial in both the onset and resolution of immune responses. Drugs targeting these mechanisms aim to suppress pro-inflammatory signals or promote regulatory, anti-inflammatory effects to treat diseases driven by immune dysregulation, such as autoimmune disease, neurodegeneration, cancer, and cardiovascular conditions. This term is not a unique molecular target but rather denotes several potential therapeutic intervention points within the broader context of immune signaling biology. In summary, "Immunomodulation through anti-inflammatory signaling pathways" does not correspond to a specific molecule or receptor, but to an entire class of regulatory axes within the immune system relevant to numerous pathological conditions.

Mechanisms vary and are specific to the actual molecular target selected within these pathways—for example, inhibition of NF-κB activation, blockade of cytokine receptors, activation of AMPK, or suppression of inflammasome activity.